CAS 2724922-85-2
:Research Grade Vensobafusp Alfa
Description:
Research Grade Vensobafusp Alfa, identified by the CAS number 2724922-85-2, is a bispecific T-cell engager (BiTE) designed for targeted cancer therapy. This innovative therapeutic agent is engineered to bind simultaneously to CD3 on T cells and a specific tumor-associated antigen, facilitating the recruitment and activation of T cells to attack cancer cells. Its structure typically includes a fusion of antibody fragments, which enhances its specificity and efficacy in targeting malignant cells while minimizing off-target effects. Vensobafusp Alfa is characterized by its ability to modulate the immune response, promoting T-cell proliferation and cytotoxic activity against tumors. As a research-grade compound, it is primarily utilized in preclinical and clinical studies to evaluate its safety, pharmacokinetics, and therapeutic potential in various malignancies. The development of such agents represents a significant advancement in immunotherapy, aiming to improve patient outcomes in oncology through precision medicine approaches.
- [Synonyms]
Sort by
The purity filter is not visible because current products do not have associated purity data for filtering.
Found 1 products.
Vensobafusp alfa
CAS:<p>Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody targeting complement protein C5, combined with the domains 1-5 of complement factor H (FH1-5). It exhibits anti-inflammatory and immunomodulatory properties. The isotype control for Vensobafusp alfa can be referred to as human IgG4(S228P) kappa.</p>Color and Shape:Liquid
